IsoRay, Inc. (NYSE MKT:ISR)

IsoRay is a clinical stage biopharmaceutical company with a strong focus on treatment of cancer who’s stock is having an incredible day in the market today. After releasing data from a study on lung cancer, the company’s stock has gone on a strong bullish path. Today, we’ll talk about the data that was released, how the market reacted, and what we can expect to see from IsoRay moving forward.

Positive Lung Cancer Data Released By ISR

IsoRay is a clinical stage innovator in seed brachytherapy and medical radioisotope applications. Today, the company released data in an online publication regarding the first major peer reviewed study of IsoRay’s Cesium-131 seeds in the treatment of lung cancer. The study showed that lung cancer patients saw improved results when treated with Cesium-131. Here’s what ISR’s CEO, Dwight Babcock had to say…

“We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking better solutions and outcomes for their patients. We are continuing to develop our product offerings internally with support from these industry leaders. With every success that has been reported, the medical community is rapidly becoming aware of the innovative alternative our Cesium-131 products offer to cancer patients.”

How ISR Reacted In The Market Following The Data Release

As mentioned above, IsoRay is having an absolutely incredible day in the market today. Simply put, when positive data is released in the small-cap biotech world, the market tends to react in an overwhelmingly positive way. Currently (1:34), ISR is trading at $2.60 per share after a massive gain of 61.49%.

What We Can Expect From IsoRay Moving Forward

Moving forward, I’m expecting to see overwhelmingly positive news from IsoRay both in the short and long term outlooks. Here’s how I see it…

  • Short Term – In the short term, I’m expecting that investor excitement revolving around IsoRay’s revolutionary treatment will continue to push the stock higher.

  • Long Term – In the long run, I think we’ll see much of the same bullish activity. At this point, IsoRay has proven that their Cesium-131 compound is incredibly effective in the treatment of non-small cell lung cancer. Through further testing, I’m sure the company will prove this without a reasonable doubt; and eventually receive FDA approval. That being said, I’m expecting to see major long term gains from ISR.